CELLINK AB (“CELLINK”) has today been informed by Erik Gatenholm, Gusten Danielsson, Héctor Martinez and Jockum Svanberg (the “founding shareholders”), that they have sold B-shares in CELLINK to Handelsbanken Fonder and the Fourth Swedish National Pension Fund (AP4) in order to repay loans that were taken to finance acquisition of shares in connection with the IPO of CELLINK in 2016. Gusten Danielsson and Jockum Svanberg is also conducting the sale to be able to participate in the proposed LTIP that is still subject to a resolution by the annual general meeting in CELLINK that will take place 13 December 2018. The following sales have been made:
|Seller||Number of sold B-shares|
After the sale, the founding shareholders owns 59% (61%) in aggregate of the capital and 71% (72%) of the votes. The founding shareholders have no intention to sell additional shares in CELLINK in the foreseeable future.
For further information, please contact:
Erik Gatenholm, CEO Gusten Danielsson, CFO
Phone: +46 73 267 00 00 Phone: +46 70 991 86 04
Phone: +1 650 515 5566 Phone: +1 857 332 2138
CELLINK has created one of the world's first universal Bioinks, today used by many of the world's most well-reputed research institutions. A Bioink can be mixed with living cells to print functional human tissues and if future research is successful, eventually, complete human organs in so-called 3D-Bioprinters. CELLINK's universal Bioink shows excellent results and can be used in both CELLINK's proprietary 3D Bioprinters and in 3D Bioprinters developed by other operators. CELLINK AB is listed at Nasdaq First North with the ticker CLNK. Erik Penser Bank AB, tel: +46 8 463 80 00, is the Company's Certified Adviser.